Abstract
Lung cancer is the leading cause of cancer death for both men and women in the United States, and similar trends are seen world wide. The lack of early diagnosis is one of the primary reasons for the high mortality rate. A number of biomarkers have been evaluated in lung cancer patients, however, their specificity and early stage diagnostic values are limited. Using traditional protein chemistry and proteomics tool we have demonstrated higher serum haptoglobin levels in small cell lung cancer (SCLC). Similar findings have been reported for other cancers including ovarian cancer and glioblastoma. Haptoglobin is an acute phase protein with at least six possible phenotypes. The six phenotypes, in combination with two post translational modifications, glycosylation and deamidation, lead to large numbers of possible haptoglobin isoforms. Recent studies indicate a possible correlation between specific haptoglobin glycosylation and particular disease conditions. In our current study, we have fractionated control and SCLC patient serum by 2-D gel electrophoresis to identify differentially expressed haptoglobin isoforms in SCLC serum samples.
Keywords: Serum, haptoglobin, Isoforms, small cell lung cancer
Current Proteomics
Title: Differential Serum Level of Specific Haptoglobin Isoforms in Small Cell Lung Cancer
Volume: 7 Issue: 1
Author(s): Ankur Shah, Harpreet Singh, Vibhu Sachdev, James Lee, Sohiya Yotsukura, Ravi Salgia and Ajit Bharti
Affiliation:
Keywords: Serum, haptoglobin, Isoforms, small cell lung cancer
Abstract: Lung cancer is the leading cause of cancer death for both men and women in the United States, and similar trends are seen world wide. The lack of early diagnosis is one of the primary reasons for the high mortality rate. A number of biomarkers have been evaluated in lung cancer patients, however, their specificity and early stage diagnostic values are limited. Using traditional protein chemistry and proteomics tool we have demonstrated higher serum haptoglobin levels in small cell lung cancer (SCLC). Similar findings have been reported for other cancers including ovarian cancer and glioblastoma. Haptoglobin is an acute phase protein with at least six possible phenotypes. The six phenotypes, in combination with two post translational modifications, glycosylation and deamidation, lead to large numbers of possible haptoglobin isoforms. Recent studies indicate a possible correlation between specific haptoglobin glycosylation and particular disease conditions. In our current study, we have fractionated control and SCLC patient serum by 2-D gel electrophoresis to identify differentially expressed haptoglobin isoforms in SCLC serum samples.
Export Options
About this article
Cite this article as:
Shah Ankur, Singh Harpreet, Sachdev Vibhu, Lee James, Yotsukura Sohiya, Salgia Ravi and Bharti Ajit, Differential Serum Level of Specific Haptoglobin Isoforms in Small Cell Lung Cancer, Current Proteomics 2010; 7 (1) . https://dx.doi.org/10.2174/157016410790979635
DOI https://dx.doi.org/10.2174/157016410790979635 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Anti-Cancer Agents in Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Microdissection and the Study of Cancer Pathways
Current Molecular Medicine Application of Gene Therapy in Diabetes Care
Infectious Disorders - Drug Targets The Therapeutic Potential of Purinergic Receptors in Alzheimer’s Disease and Promising Therapeutic Modulators
Mini-Reviews in Medicinal Chemistry miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug
Current Protein & Peptide Science PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance
Current Cancer Drug Targets Factors Affecting the Metabolite Productions in Endophytes: Biotechnological Approaches for Production of Metabolites
Current Medicinal Chemistry Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Downstream Carcinogenesis Signaling Pathways by Green Tea Polyphenols: A Translational Perspective of Chemoprevention and Treatment for Cancers
Current Drug Metabolism Synthesis, Topoisomerase I Inhibitory and Cytotoxic Activities of Chromone Derivatives
Medicinal Chemistry A Review of Recent Advancements in Anti-tubercular Molecular Hybrids
Current Medicinal Chemistry Editorial [Hot Topic:Non-Receptor Tyrosine Kinases as Molecular Targets for Patient Tailored Cancer Therapy (Guest Editors: F.M. Uckun, A. Vassilev and H. Tibbles)]
Anti-Cancer Agents in Medicinal Chemistry Lambert-Eaton Myasthenic Syndrome: A Very Rare and Tortuously Exasperating Facet of Pre-Synaptic Disorder of Neuromuscular Junction
Current Immunology Reviews (Discontinued) Synthesis and Biological Evaluation of New Piperazine Substituted 3, 5-Diarylisoxazolines
Current Organic Synthesis Chemometric Approach to Develop and Validate RP-HPLC Method for Estimation of Erlotinib Hydrochloride in Nano Structured Lipid Carriers
Current Pharmaceutical Analysis Docetaxel (Taxotere) in the Treatment of Non-Small Cell Lung Cancer
Current Medicinal Chemistry Combined Modality Treatment of Limited Stage Small Cell Carcinoma of the Lung
Reviews on Recent Clinical Trials